Sonar Clinical Research — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$226,421	14
2024	Research	$229,315	27
2023	Research	$114,141	20

Breakdown

Who paid Research payments · program years 2023–2025

GlaxoSmithKline, LLC. $371,702 45 payments
Novo Nordisk AS $158,327 10 payments
Novartis Pharmaceuticals Corporation $22,637 3 payments
Arena Pharmaceuticals, Inc. $17,210 3 payments

Studies the money was for Research payments · program years 2023–2025

A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Para $371,702 45 payments
4202-Hem-301 $158,327 10 payments
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) $22,637 3 payments
A Phase 23 Randomized Multicenter Study of Gbt021601 Administered Orally to Participants With Sickle Cell Disease and An Openlabel Pharmacokinetics Study in Pediatric Participants With Sickle Cell Disease $17,210 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.